Member Info for Newuncle

GMS,

At 200 CIRT tests a month the income would be in the £400k a month range, hardly chicken feed and a substantially profitable revenue stream to help offset costs here.

And when it moves properly buyers will be all over it.

Laura,

I just say what I see, yes buys are there but always seem to be offset by sells, nothing sinister intended just my observations on a daily basis here and why SP can't break out of its current range. That's it.

There are buyers who will pile in if it starts moving up but there's always enough sellers to kill it every time.

-13% now

-9% today, says it all really

Guess the BoD kept kicking that can down the road and hoped something would materialise to deliver a stronger set of numbers and steady the financials going forwards. That's trouble when you have brilliant scientists who great at doing the clever and complicated stuff but not focused on the commercial realities the company was facing. Not too late get it sorted but if they simply think they can keep on tapping the market for funds anyway then why should they even bother exploring other options. Them stating that they raised cash at a premium to the share price at the time previously is meaningless right now and if they need another £5m or £10m to get the runway they need to sort it now or potentially watch the share price drift down until they make a decision.

Company has to bite the bullet now and partner with a major player if they want to fully commercialise their PSE and CIRT tests. It's an essential game plan that should have been mapped out long before now.

Going it alone or relying on Doctor to Doctor as a route market clearly isn't working.

Incredible to see that they are talking to potential partners on their other pipeline projects but nothing I can see to suggest the same for PSE or CIRT tests. Yes they got BUPA on board in the UK and confirmed they are back at 4 CIRT tests a day (until the next expected/planned drop) or unexpected leave of absence by the individual responsible for managing UK CIRT sales (really, just one person?, is this a company a global player PLC or are sales being operated out of of someone's living room?).

The one positive I can see that is that management will be focused on their financial position to avoid having to do yet another placing and will have to work fast to address this. Maybe someone should ask Peter Jones or Deborah Meadon to pay them a visit and show them how it's done?

01234 go f**k yourself

And of course the lack of commercial awareness means the actual test that could be saving people from horrible biopsies etc etc is still not out there. God knows when the UK PSE test might come in via the NHS now.

I bet all the news channels and tomorrows papers will be full of prostate cancer testing with interviews of experts etc and I can guarantee you not one of them will mention Oxford Biodynamics or their 94% PSE Test.

Fwiw

rar10017 Jan '24 - 16:27 - 107 of 107 0 0 0

Big Pharma taking over monetizing on tests and leaving OBD to do science only is very obviously the best scenario as these results show all too clearly.

Good at science, clueless at business. No idea how to treat shareholders as their rns's show.

I won't bother to look at this crowd until there's news of a takeover in some form.

Fwiw

VincentVega

RE: Oxford Biodyn vs Ciz business modelsToday 16:21

I’ve just watched their webinar.

They’re 6mths behind setting up a cohesive sales structure. They’ll need additional funding in the near term due to this and their less than satisfactory product uptake.

ReplyRecommendReport Post

Techtonic

Oxford Biodyn vs Ciz business modelsToday 14:41

OBD (Prostate cancer test) today suffering 25% fall due to making a whopping £10Mill loss.

This provides a great comparator for our respective business models.

OBD has great science and a superb test but they are doing all the leg work and funding themselves.

Ciz seem to have great science (soon to be proven on a mass scale, hopefully) but carries none of the baggage of in-house majority funding.

By outsourcing to our partners for a % it means we steer clear of the business cash pitfalls.

190 participants

I don't get it, supposed to be 190 on that webinar, feedback positive, shares stuck at -23% for the day and sellers still exiting.....is anyone actually a buyer?

They need to get a shift on as placings need to be organised etc etc etc, will there be a vote at the AGM?

So a placing it is, anyone guess the price and how much dilution?

Price is dropping back again.......

Depends on definition of no discount from here?

From todays RNS, the boring bit that most of us don't bother reading:

The consolidated financial statements are presented in pounds sterling (GBP), which is also the Company's functional currency.

Going concern

In assessing the appropriateness of adopting the going concern assumption, the Group and Parent Company has prepared a detailed budget ("the budget") for the two-year period ending 30 September 2025. The budget includes:

· estimates of likely revenue arising from EpiSwitch® CiRT and EpiSwitch® PSE (based on the Group's own assessments of market opportunities);

· anticipated revenues from contracts with pharmaceutical partners;

· expected income from existing grants and awards;

· operating costs reflecting the current cost base (plus inflationary increases), with some increases in activity to support the commercial tests already launched; and

· capital expenditure, primarily to maintain and extend the Group's patent estate.

Combined revenue and other operating income during the year ended 30 September 2023 was increased compared to the previous year, but the Group remained lossmaking with income significantly exceeded by operating costs, which included spending necessary to expedite the development and launch of the PSE test during the year. The Group was able to maintain its cash reserves during the year, including through the raising of £9.3m (before costs) through a placing, subscription and open offer in October 2022 and £6.1m (before costs) through a placing, subscription and PrimaryBid offer in August 2023.

The Board considers that the budget represents a reasonable best estimate of the Group's performance over the period to 30 September 2025 and the Directors are satisfied that in the scenario modelled in the budget, the Group and Parent Company would be able to continue as a going concern. The Directors note, however, that the budget includes estimates of product and contract revenue reflecting significant increases in the volume of CiRT tests to be ordered in FY24 compared to FY23, significant increases, post-launch, in orders of PSE tests and expectations of a number of new contracts with pharma customers. Forecast cash balances in the budget, whilst positive throughout the period covered, are expected to be reduced to a low level relative to the Group's cost base through much of 2024.